The estimated Net Worth of Mark J Foley is at least $30.7 Million dollars as of 6 March 2024. Mr. Foley owns over 30,000 units of Revance Therapeutics Inc stock worth over $6,681,779 and over the last 9 years he sold RVNC stock worth over $6,866,970. In addition, he makes $17,190,400 as President, Chief Executive Officer, and Director at Revance Therapeutics Inc.
Mark has made over 9 trades of the Revance Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of RVNC stock worth $209,400 on 6 March 2024.
The largest trade he's ever made was selling 70,447 units of Revance Therapeutics Inc stock on 2 February 2022 worth over $2,433,944. On average, Mark trades about 7,058 units every 50 days since 2015. As of 6 March 2024 he still owns at least 1,015,468 units of Revance Therapeutics Inc stock.
You can see the complete history of Mr. Foley stock trades at the bottom of the page.
Mark J. Foley serves as President, Chief Executive Officer, Director of the Company. Mr. Foley has served as a director of our Company since September 2017. Mr. Foley has more than 25 years of operational and investment experience in the healthcare arena. He has been a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments from 2004 to 2017. Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ), serving from 2012 through the company’s acquisition in 2017 by Allergan (AGN). Prior to ZELTIQ, Mr. Foley held a variety of senior operating roles in large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where he was the founder and CEO. He is a board member at Glaukos (GKOS) and also serves as Chairman of ULab, HintMD and Arrinex. Mr. Foley received a Bachelor of Arts degree from the University of Notre Dame. Our board of directors believes that Mr. Foley’s financial expertise, experience at multiple public pharmaceutical companies and his expertise with the development and commercialization in medical device and biotechnology industries make him qualified to serve on our board of directors.
As the President, Chief Executive Officer, and Director of Revance Therapeutics Inc, the total compensation of Mark Foley at Revance Therapeutics Inc is $17,190,400. There are no executives at Revance Therapeutics Inc getting paid more.
Mark Foley is 54, he's been the President, Chief Executive Officer, and Director of Revance Therapeutics Inc since 2019. There are 10 older and 5 younger executives at Revance Therapeutics Inc. The oldest executive at Revance Therapeutics Inc is Robert Byrnes, 75, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC., 1222 DEMONBREUN STREET, 20TH FLOOR, NASHVILLE, TN, 37203.
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli, and Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
Revance Therapeutics Inc executives and other stock owners filed with the SEC include: